WASHINGTON (AP) — The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes.
The medicine, Alprolix (all-PRO’licks), is for preventing or shortening bleeding episodes in adults and children with hemophilia B, the second-most common type. It affects about 3,300 Americans, mostly males.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.